CD276 and breast cancer: In addition, anti-PD-1/PD-L1 mAb combined with B7H3 blockers (anti-B7H3 mAb or V9302) could transform “immune desert” tumors into “hot”, improve the curative benefits in metastatic or advanced breast cancer (91).